China 
Africa 
Explore chapters and articles related to this topic
Muscle Pain (Myalgia)
Published in Charles Theisler, Adjuvant Medical Care, 2023
Myalgia, or muscle pain, is a symptom of many different diseases and disorders. Muscle pain can be localized (e.g., injury, overuse) or throughout the body (e.g., infections, illness, or side effects from medications such as anticonvulsants, antibiotics, anticancer agents, statins, and diuretics).
Autoimmune conditions
Published in Ibrahim Natalwala, Ammar Natalwala, E Glucksman, MCQs in Neurology and Neurosurgery for Medical Students, 2022
Ibrahim Natalwala, Ammar Natalwala, E Glucksman
FALSE – Muscle weakness is usually proximal and symmetrical and thus patients with autoimmune myopathies have difficulty getting up from chairs, climbing stairs or brushing their hair. Patients can have significant myalgia as a result of the inflammation. Creatine kinase is usually raised. Diagnosis is made using electromyography and muscle biopsy.
The Musculoskeletal System and Its Disorders
Published in Walter F. Stanaszek, Mary J. Stanaszek, Robert J. Holt, Steven Strauss, Understanding Medical Terms, 2020
Walter F. Stanaszek, Mary J. Stanaszek, Robert J. Holt, Steven Strauss
Myalgia denotes pain in a muscle. Injury can involve myorrhexis, a tear in the muscle, or miyostasis, stretching. Muscular spasms may cause myotomes or myospasm.
Neurological symptoms and findings in COVID-19: a prospective clinical study
Published in Neurological Research, 2022
Cansu Köseoğlu Toksoy, Tunzala Yavuz, Semiha Orhan, Petek Şarlak Konya, Derya Korkmaz, Havva Tünay, Erhan Bozkurt, İbrahim Güven Coşğun, Neşe Demirtürk, İsmet Doğan, Ülkü Türk Börü
Most studies of neurological symptoms and signs seen in COVID-19 infection are retrospective studies from medical records [4–6]. In a retrospective study of 214 patients in China, neurologic manifestations were found in 36.4% of patients [4]. In our study, this rate was much higher. This may be due to the prospective and detailed questioning and neurological examination of patients. In a multicenter retrospective cohort study conducted in China, the frequency of neurological manifestations was found to be 3.5% [5]. This rate is quite low. This may be explained by the fact that patients with only nonspecific symptoms such as headache, dizziness, fatigue and myalgia were excluded from the study according to the protocol. This is because, as in our study, the most common symptom in these studies was recorded as myalgia
Clinical practice guidance for Sjögren’s syndrome in pediatric patients (2018) – summarized and updated
Published in Modern Rheumatology, 2021
Minako Tomiita, Ichiro Kobayashi, Yasuhiko Itoh, Yuzaburo Inoue, Naomi Iwata, Hiroaki Umebayashi, Nami Okamoto, Yukiko Nonaka, Ryoki Hara, Masaaki Mori
Musculoskeletal diseases: Arthralgia or arthritis is usually non-erosive and responds to NSAIDs. Hydroxychloroquine is widely used for arthritis in SS throughout the world but is not approved by Social Health Insurance of Japan [66,67]. Methotrexate (MTX) is considered for NSAID-resistant arthralgia/arthritis despite the lack of evidence. A short course of systemic GC may be considered. Myalgia without apparent inflammation is managed as neuropathic pain [68]. Systemic GC is a first-line drug, although lacking randomized controlled trial (RCT) validation, and concomitant use of disease modifying anti-rheumatic drugs (DMARDs) such as MTX, mycophenolate mofetil (MMF), tacrolimus, or intravenous gammaglobulin (IVIG) based on evidence in dermatomyositis/polymyositis has been reported in adult SS cases with refractory myositis [69–71].
The insidious impact of under-diagnosed proximal weakness induced by statins
Published in Expert Review of Neurotherapeutics, 2021
Panza and colleagues reported 47 patients with SAMS drawn from 3 diverse trials [29]. Maximal isometric handgrip strength, resting respiratory exchange ratio (RER), and knee extensor isometric and isokinetic and elbow flexor forces were measured using a Biodex System 3 dynamometer (Biodex Medical, Shirley, NY). Most subjects were tested on a statin or placebo after only 8 weeks of intake. They concluded that no large, systematic muscle strength changes occur in patients with myalgia. However, the data summary tables did in fact reveal several group differences that were statistically significant – isometric knee extension for average peak torque and isokinetic knee extension at 60 degrees/sec were reduced by a statin. Grip strength as expected was not affected. They did not test the muscle groups that are typically most affected by a myopathy, the hip flexors, extensors and abductors, the knee flexors, and neck flexors. Also, the duration of statin intake, just 8 weeks, was on the short end of the evolution of initial weakness in our experience. Yet there was demonstrable weakness in their underpowered mix of trials. The investigators recommended further study of dynamometric testing.